<DOC>
	<DOCNO>NCT01468493</DOCNO>
	<brief_summary>The purpose study determine whether improved responsiveness treatment achieve CsA patient steroid-resistant steroid-dependent FSGS could explain CsA 's inhibitory action circulate suPAR expression .</brief_summary>
	<brief_title>A Prospective Controlled Study Serum suPAR CsA-treated FSGS Patients</brief_title>
	<detailed_description />
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<criteria>Age entry 14 70 year biopsyproven primary FSGS proteinuria &gt; =3 g/day without corticosteroid CsA treatment entry Chronic Inflammatory Diseases malignant tumor diabetes mellitus contraindication treatment corticosteroid CsA treatment untolerate unwilling accept corticosteroid CsA treatment</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>FSGS</keyword>
	<keyword>suPAR</keyword>
</DOC>